Clinical Trial Details
| Trial ID: | L4206 |
| Source ID: | NCT01945216 |
| Associated Drug: | Alogliptin |
| Title: | Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI" |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | YES |
| Results: | https://ClinicalTrials.gov/show/NCT01945216/results |
| Conditions: | Type 2 Diabetes Mellitus Who Have Been Examined at a Medical Institution |
| Interventions: | DRUG: Alogliptin |
| Outcome Measures: | Primary: Number of Participants Who Experience at Least One Adverse Events, Up to Month 36|Change From Baseline in Glycosylated Hemoglobin (HbA1c), The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at month 36 relative to baseline., Baseline, Months 1, 3, 6, 12, 18, 24, 30, 36 and final assessment (up to Month 36) | Secondary: Change From Baseline in Fasting Blood Glucose, The change in the value of fasting blood glucose collected at month 36 relative to baseline., Baseline, Months 1, 3, 6, 12, 18, 24, 30, 36 and final assessment (up to Month 36) |
| Sponsor/Collaborators: | Sponsor: Takeda |
| Gender: | ALL |
| Age: | CHILD, ADULT, OLDER_ADULT |
| Phases: | |
| Enrollment: | 3317 |
| Study Type: | OBSERVATIONAL |
| Study Designs: | Observational Model: |Time Perspective: p |
| Start Date: | 2010-07-08 |
| Completion Date: | 2015-10-31 |
| Results First Posted: | 2018-11-08 |
| Last Update Posted: | 2019-11-19 |
| Locations: | Osaka, Japan |
| URL: | https://clinicaltrials.gov/show/NCT01945216 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|